2011-14253. Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 28, 2011, Alltech Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Methcathinone (1237)	I
N-ethylamphetamine (1475)	I
N,N-dimethylamphetamine (1480)	I
4-methylaminorex (cis isomer) (1590)	I
Alpha-ethyltryptamine (7249)	I
Lysergic acid diethylamide (7315)	I
2,5-dimethoxy-4-(n)-propylthiophenethylamine
(7348)	I
Tetrahydrocannabinols (7370)	I
Mescaline (7381)	I
4-bromo-2,5-dimethoxy-amphetamine (7391)	I
4-Bromo-2,5-dimethoxyphenethylamine (7392)	I
4-methyl-2,5-dimethoxy-amphetamine (7395)	I
2,5-dimethoxyamphetamine (7396)	I
2,5-dimethoxy-4-ethylamphetamine (7399)	I
3,4-methylenedioxy amphetamine (7400)	I
N-hydroxy-3,4-methylenedioxyamphetamine (7402)	I
3,4-methylenedioxy-N-ethylamphetamine (7404)	I
3,4-methylenedioxymethamphetamine (MDMA) (7405)	I
4-methoxyamphetamine (7411)	I
Alpha-methyltryptamine (7432)	I
Bufotenine (7433)	I
Diethyltryptamine (7434)	I
Dimethyltryptamine (7435)	I
Psilocybin (7437)	I
Psilocyn (7438)	I
5-methoxy-N,N-diisopropyltryptamine (7439)	I
N-ethyl-1-phenylcyclohexylamine (7455)	I
1-(1-phenylcyclohexyl)-pyrrolidine (7458)	I
1-[1-(2-thienyl)-cyclohexyl]-piperidine (7470)	I
Dihydromorphine (9145)	I
Normorphine (9313)	I
Methamphetamine (1105)	II
1-phenylcyclohexylamine (7460)	II
Phencyclidine (7471)	II
Phenylacetone (8501)	II
1-piperidinocyclohexane-carbonitrile (8603)	II
Cocaine (9041)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Ecgonine (9180)	II
Meperidine intermediate-B (9233)	II
Noroxymorphone (9668)	II

The company plans to manufacture high purity drug standards used for analytical applications only in clinical, toxicological, and forensic laboratories.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a).

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than August 8, 2011.

Dated: June 1, 2011.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.